The complement system in cancer: Ambivalence between tumour destruction and promotion

Immunobiology

Volumn 222, Issue 1, 2017, Pages 45-54

  Mamidi, Srinivas ^a   Höne, Simon ^a   Kirschfink, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

C3a; C5a; Cancer; Complement regulatory proteins; Complement dependent cytotoxicity; Opsonisation

Indexed keywords

ALEMTUZUMAB; CD11B ANTIGEN; CD18 ANTIGEN; CD59 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C2A; COMPLEMENT COMPONENT C2B; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; DECAY ACCELERATING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; INTERLEUKIN 10; MEMBRANE COFACTOR PROTEIN; OFATUMUMAB; REACTIVE OXYGEN METABOLITE; RITUXIMAB; SMALL INTERFERING RNA; UNINDEXED DRUG; COMPLEMENT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL MEDIATED CYTOTOXICITY; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONFORMATIONAL TRANSITION; CYTOKINE PRODUCTION; GENE SILENCING; HUMAN; IMMUNOREGULATION; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; CYTOTOXICITY; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PATHOLOGY; PROCEDURES; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASMS; PROTEIN ENGINEERING;

EID: 84949633393     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2015.11.008     Document Type: Review

References (138)

1. Aagaard, L., Rossi, J.J., RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 59 (2007), 75–86.
2. Ajona, D., Castano, Z., Garayoa, M., Zudaire, E., Pajares, M.J., Martinez, A., Cuttitta, F., Montuenga, L.M., Pio, R., Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res. 64 (2004), 6310–6318.
3. Baig, N.A., Taylor, R.P., Lindorfer, M.A., Church, A.K., LaPlant, B.R., Pettinger, A.M., Shanafelt, T.D., Nowakowski, G.S., Zent, C.S., Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J. Immunol. 192 (2014), 1620–1629.
4. Bannerji, R., Kitada, S., Flinn, I.W., Pearson, M., Young, D., Reed, J.C., Byrd, J.C., Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J. Clin. Oncol. 21 (2003), 1466–1471.
5. Bjorge, L., Matre, R., Down-regulation of CD59 (protectin) expression on human colorectal adenocarcinoma cell lines by levamisole. Scand. J. Immunol. 42 (1995), 512–516.
6. Bjorge, L., Hakulinen, J., Wahlstrom, T., Matre, R., Meri, S., Complement-regulatory proteins in ovarian malignancies. Int. J. Cancer 70 (1997), 14–25.
7. Bjorge, L., Hakulinen, J., Vintermyr, O.K., Jarva, H., Jensen, T.S., Iversen, O.E., Meri, S., Ascitic complement system in ovarian cancer. Br. J. Cancer 92 (2005), 895–905.
8. Blok, V.T., Gelderman, K.A., Tijsma, O.H., Daha, M.R., Gorter, A., Cytokines affect resistance of human renal tumour cells to complement-mediated injury. Scand. J. Immunol. 57 (2003), 591–599.
9. Bologna, L., Gotti, E., Da Roit, F., Intermesoli, T., Rambaldi, A., Introna, M., Golay, J., Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J. Immunol. 190 (2013), 231–239.
10. Bottazzi, B., Vouret-Craviari, V., Bastone, A., De Gioia, L., Matteucci, C., Peri, G., Spreafico, F., Pausa, M., D'Ettorre, C., Gianazza, E., Tagliabue, A., Salmona, M., Tedesco, F., Introna, M., Mantovani, A., Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J. Biol. Chem. 272 (1997), 32817–32823.
11. Burnett, J.C., Rossi, J.J., RNA-based therapeutics: current progress and future prospects. Chem. Biol. 19 (2012), 60–71.
12. Carroll, M.C., The complement system in regulation of adaptive immunity. Nat. Immunol. 5 (2004), 981–986.
13. Cheung, N.K., Walter, E.I., Smith-Mensah, W.H., Ratnoff, W.D., Tykocinski, M.L., Medof, M.E., Decay-accelerating factor protects human tumour cells from complement-mediated cytotoxicity in vitro. J. Clin. Investig. 81 (1988), 1122–1128.
14. Cinci, M., Mamidi, S., Li, W., Fehring, V., Kirschfink, M., Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack. Target Oncol.(November 15), 2014 [Epub ahead of print].
15. Corrales, L., Ajona, D., Rafail, S., Lasarte, J.J., Riezu-Boj, J.I., Lambris, J.D., Rouzaut, A., Pajares, M.J., Montuenga, L.M., Pio, R., Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J. Immunol. 189 (2012), 4674–4683.
16. Coulthard, L.G., Woodruff, T.M., Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. J. Immunol. 194 (2015), 3542–3548.
17. Cragg, M.S., Glennie, M.J., Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103 (2004), 2738–2743.
18. Cui, T., Chen, Y., Knosel, T., Yang, L., Zoller, K., Galler, K., Berndt, A., Mihlan, M., Zipfel, P.F., Petersen, I., Human complement factor H is a novel diagnostic marker for lung adenocarcinoma. Int. J. Oncol. 39 (2011), 161–168.
19. Czauderna, F., Fechtner, M., Dames, S., Aygun, H., Klippel, A., Pronk, G.J., Giese, K., Kaufmann, J., Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31 (2003), 2705–2716.
20. Deban, L., Jarva, H., Lehtinen, M.J., Bottazzi, B., Bastone, A., Doni, A., Jokiranta, T.S., Mantovani, A., Meri, S., Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J. Immunol. 181 (2008), 8433–8440.
21. Dechant, M., Weisner, W., Berger, S., Peipp, M., Beyer, T., Schneider-Merck, T., Lammerts van Bueren, J.J., Bleeker, W.K., Parren, P.W., van de Winkel, J.G., Valerius, T., Complement-dependent tumour cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res. 68 (2008), 4998–5003.
22. Di Gaetano, N., Xiao, Y., Erba, E., Bassan, R., Rambaldi, A., Golay, J., Introna, M., Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Haematol. 114 (2001), 800–809.
23. Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., Golay, J., Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171 (2003), 1581–1587.
24. Doni, A., Garlanda, C., Bottazzi, B., Meri, S., Garred, P., Mantovani, A., Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology 217 (2012), 1122–1128.
25. Donin, N., Jurianz, K., Ziporen, L., Schultz, S., Kirschfink, M., Fishelson, Z., Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin. Exp. Immunol. 131 (2003), 254–263.
26. Dufes, C., Al Robaian, M., Somani, S., Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells. Ther. Deliv. 4 (2013), 629–640.
27. Elvington, M., Huang, Y., Morgan, B.P., Qiao, F., van Rooijen, N., Atkinson, C., Tomlinson, S., A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood 119 (2012), 6043–6051.
28. Elvington, M., Scheiber, M., Yang, X., Lyons, K., Jacqmin, D., Wadsworth, C., Marshall, D., Vanek, K., Tomlinson, S., Complement-dependent modulation of antitumour immunity following radiation therapy. Cell Rep. 8 (2014), 818–830.
29. Fearon, D.T., Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc. Natl. Acad. Sci. U. S. A. 76 (1979), 5867–5871.
30. Filleur, S., Courtin, A., Ait-Si-Ali, S., Guglielmi, J., Merle, C., Harel-Bellan, A., Clezardin, P., Cabon, F., SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumour resistance to antiangiogenic thrombospondin-1 and slows tumour vascularization and growth. Cancer Res. 63 (2003), 3919–3922.
31. Gaboriaud, C., Thielens, N.M., Gregory, L.A., Rossi, V., Fontecilla-Camps, J.C., Arlaud, G.J., Structure and activation of the C1 complex of complement: unraveling the puzzle. Trends Immunol. 25 (2004), 368–373.
32. Gasque, P., Julen, N., Ischenko, A.M., Picot, C., Mauger, C., Chauzy, C., Ripoche, J., Fontaine, M., Expression of complement components of the alternative pathway by glioma cell lines. J. Immunol. 149 (1992), 1381–1387.
33. Gasque, P., Morgan, B.P., Legoedec, J., Chan, P., Fontaine, M., Human skeletal myoblasts spontaneously activate allogeneic complement but are resistant to killing. J. Immunol. 156 (1996), 3402–3411.
34. Gasque, P., Thomas, A., Fontaine, M., Morgan, B.P., Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J. Neuroimmunol. 66 (1996), 29–40.
35. Geis, N., Zell, S., Rutz, R., Li, W., Giese, T., Mamidi, S., Schultz, S., Kirschfink, M., Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumour cells to complement attack in vitro. Curr. Cancer Drug Targets 10 (2010), 922–931.
36. Gelderman, K.A., Blok, V.T., Fleuren, G.J., Gorter, A., The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab. Investig. 82 (2002), 483–493.
37. Gelderman, K.A., Kuppen, P.J., Bruin, W., Fleuren, G.J., Gorter, A., Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. Eur. J. Immunol. 32 (2002), 128–135.
38. Gelderman, K.A., Tomlinson, S., Ross, G.D., Gorter, A., Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 25 (2004), 158–164.
39. Gelderman, K.A., Lam, S., Sier, C.F., Gorter, A., Cross-linking tumour cells with effector cells via CD55 with a bispecific mAb induces beta-glucan-dependent CR3-dependent cellular cytotoxicity. Eur. J. Immunol. 36 (2006), 977–984.
40. Glennie, M.J., French, R.R., Cragg, M.S., Taylor, R.P., Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44 (2007), 3823–3837.
41. Gminski, J., Mykala-Ciesla, J., Machalski, M., Drozdz, M., Najda, J., Immunoglobulins and complement components levels in patients with lung cancer. Rom. J. Intern. Med. 30 (1992), 39–44.
42. Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., Introna, M., CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98 (2001), 3383–3389.
43. Golay, J., Manganini, M., Rambaldi, A., Introna, M., Effect of alemtuzumab on neoplastic B cells. Haematologica 89 (2004), 1476–1483.
44. Gorter, A., Meri, S., Immune evasion of tumour cells using membrane-bound complement regulatory proteins. Immunol. Today 20 (1999), 576–582.
45. Hajela, K., Kojima, M., Ambrus, G., Wong, K.H., Moffatt, B.E., Ferluga, J., Hajela, S., Gal, P., Sim, R.B., The biological functions of MBL-associated serine proteases (MASPs). Immunobiology 205 (2002), 467–475.
46. Harris, C.L., Kan, K.S., Stevenson, G.T., Morgan, B.P., Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59. Clin. Exp. Immunol. 107 (1997), 364–371.
47. Holers, V.M., Rohrer, B., Tomlinson, S., CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv. Exp. Med. Biol. 735 (2013), 137–154.
48. Horl, S., Banki, Z., Huber, G., Ejaz, A., Mullauer, B., Willenbacher, E., Steurer, M., Stoiber, H., Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells. Haematologica 98 (2013), 1939–1947.
49. Horl, S., Banki, Z., Huber, G., Ejaz, A., Windisch, D., Muellauer, B., Willenbacher, E., Steurer, M., Stoiber, H., Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity. Leukemia 27 (2013), 2200–2208.
50. Hsu, Y.F., Ajona, D., Corrales, L., Lopez-Picazo, J.M., Gurpide, A., Montuenga, L.M., Pio, R., Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumour growth in vivo. Mol. Cancer, 9, 2010, 139.
51. Huber-Lang, M., Sarma, J.V., Zetoune, F.S., Rittirsch, D., Neff, T.A., McGuire, S.R., Lambris, J.D., Warner, R.L., Flierl, M.A., Hoesel, L.M., Gebhard, F., Younger, J.G., Drouin, S.M., Wetsel, R.A., Ward, P.A., Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12 (2006), 682–687.
52. Hyc, A., Osiecka-Iwan, A., Strzelczyk, P., Moskalewski, S., Effect of IL-1beta TNF-alpha and IL-4 on complement regulatory protein mRNA expression in human articular chondrocytes. Int. J. Mol. Med. 11 (2003), 91–94.
53. Idusogie, E.E., Wong, P.Y., Presta, L.G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., Mulkerrin, M.G., Engineered antibodies with increased activity to recruit complement. J. Immunol. 166 (2001), 2571–2575.
54. Imai, M., Ohta, R., Varela, J.C., Song, H., Tomlinson, S., Enhancement of antibody-dependent mechanisms of tumour cell lysis by a targeted activator of complement. Cancer Res. 67 (2007), 9535–9541.
55. Jarvis, G.A., Li, J., Hakulinen, J., Brady, K.A., Nordling, S., Dahiya, R., Meri, S., Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int. J. Cancer 71 (1997), 1049–1055.
56. Jurianz, K., Maslak, S., Garcia-Schuler, H., Fishelson, Z., Kirschfink, M., Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. Immunopharmacology 42 (1999), 209–218.
57. Jurianz, K., Ziegler, S., Donin, N., Reiter, Y., Fishelson, Z., Kirschfink, M., K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int. J. Cancer 93 (2001), 848–854.
58. Kemper, C., Atkinson, J.P., T-cell regulation: with complements from innate immunity. Nat. Rev. Immunol. 7 (2007), 9–18.
59. Kennedy, A.D., Solga, M.D., Schuman, T.A., Chi, A.W., Lindorfer, M.A., Sutherland, W.M., Foley, P.L., Taylor, R.P., An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 101 (2003), 1071–1079.
60. Klausz, K., Berger, S., Lammerts van Bueren, J.J., Derer, S., Lohse, S., Dechant, M., van de Winkel, J.G., Peipp, M., Parren, P.W., Valerius, T., Complement-mediated tumour-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Sci. 102 (2011), 1761–1768.
61. Klein, E., Di Renzo, L., Yefenof, E., Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells. Mol. Immunol. 27 (1990), 1343–1347.
62. Kojima, A., Iwata, K., Seya, T., Matsumoto, M., Ariga, H., Atkinson, J.P., Nagasawa, S., Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J. Immunol. 151 (1993), 1519–1527.
63. Kolev, M., Towner, L., Donev, R., Complement in cancer and cancer immunotherapy. Arch. Immunol. Ther. Exp. (Warsz.) 59 (2011), 407–419.
64. Kuraya, M., Yefenof, E., Klein, G., Klein, E., Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis. Eur. J. Immunol. 22 (1992), 1871–1876.
65. Lindorfer, M.A., Beum, P.V., Taylor, R.P., CD20 mAb-mediated complement dependent cytotoxicity of tumour cells is enhanced by blocking the action of factor I. Antibodies 2 (2013), 598–616.
66. Liszewski, M.K., Farries, T.C., Lublin, D.M., Rooney, I.A., Atkinson, J.P., Control of the complement system. Adv. Immunol. 61 (1996), 201–283.
67. Lucas, S.D., Karlsson-Parra, A., Nilsson, B., Grimelius, L., Akerstrom, G., Rastad, J., Juhlin, C., Tumour-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum. Pathol. 27 (1996), 1329–1335.
68. Macor, P., Mezzanzanica, D., Cossetti, C., Alberti, P., Figini, M., Canevari, S., Tedesco, F., Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res. 66 (2006), 3876–3883.
69. Macor, P., Tripodo, C., Zorzet, S., Piovan, E., Bossi, F., Marzari, R., Amadori, A., Tedesco, F., In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumour activity of rituximab. Cancer Res. 67 (2007), 10556–10563.
70. Macor, P., Secco, E., Mezzaroba, N., Zorzet, S., Durigutto, P., Gaiotto, T., De Maso, L., Biffi, S., Garrovo, C., Capolla, S., Tripodo, C., Gattei, V., Marzari, R., Tedesco, F., Sblattero, D., Bispecific antibodies targeting tumour-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. Leukemia 29 (2015), 406–414.
71. Mamidi, S., Cinci, M., Hasmann, M., Fehring, V., Kirschfink, M., Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumour activity of trastuzumab and pertuzumab. Mol. Oncol. 7 (2013), 580–594.
72. Mamidi, S., Hone, S., Teufel, C., Sellner, L., Zenz, T., Kirschfink, M., Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. Oncoimmunology, 4, 2015, e979688.
73. Maness, P.F., Orengo, A., Serum complement levels in patients with digestive tract carcinomas and other neoplastic diseases. Oncology 34 (1977), 87–89.
74. Markiewski, M.M., DeAngelis, R.A., Benencia, F., Ricklin-Lichtsteiner, S.K., Koutoulaki, A., Gerard, C., Coukos, G., Lambris, J.D., Modulation of the antitumour immune response by complement. Nat. Immunol. 9 (2008), 1225–1235.
75. Matsutani, M., Suzuki, T., Hori, T., Terao, H., Takakura, K., Nishioka, K., Cellular immunity and complement levels in hosts with brain tumours. Neurosurg. Rev. 7 (1984), 29–35.
76. Medicus, R.G., Melamed, J., Arnaout, M.A., Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules. Eur. J. Immunol. 13 (1983), 465–470.
77. Medof, M.E., Iida, K., Mold, C., Nussenzweig, V., Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J. Exp. Med. 156 (1982), 1739–1754.
78. Mendonca, L.S., Firmino, F., Moreira, J.N., Pedroso de Lima, M.C., Simoes, S., Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug. Chem. 21 (2010), 157–168.
79. Meri, S., Morgan, B.P., Davies, A., Daniels, R.H., Olavesen, M.G., Waldmann, H., Lachmann, P.J., Human protectin (CD59), an 18,000–20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71 (1990), 1–9.
80. Middleton, O., Cosimo, E., Dobbin, E., McCaig, A.M., Clarke, C., Brant, A.M., Leach, M.T., Michie, A.M., Wheadon, H., Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL. Leukemia 29 (2015), 107–114.
81. Morgan, B.P., Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem. J. 264 (1989), 1–14.
82. Morgan, B.P., Dankert, J.R., Esser, A.F., Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J. Immunol. 138 (1987), 246–253.
83. Muller-Eberhard, H.J., The membrane attack complex of complement. Annu. Rev. Immunol. 4 (1986), 503–528.
84. Nicholson-Weller, A., Wang, C.E., Structure and function of decay accelerating factor CD55. J. Lab. Clin. Med. 123 (1994), 485–491.
85. Niculescu, F., Rus, H.G., Retegan, M., Vlaicu, R., Persistent complement activation on tumour cells in breast cancer. Am. J. Pathol. 140 (1992), 1039–1043.
86. Nilsson Ekdahl, K., Nilsson, B., Phosphorylation of complement component C3 after synthesis in U937 cells by a putative protein kinase, casein kinase 2, which is regulated by CD11b: evidence that membrane-bound proteases preferentially cleave phosphorylated C3. Biochem. J. 328:Pt. 2 (1997), 625–633.
87. Nitta, H., Wada, Y., Kawano, Y., Murakami, Y., Irie, A., Taniguchi, K., Kikuchi, K., Yamada, G., Suzuki, K., Honda, J., Wilson-Morifuji, M., Araki, N., Eto, M., Baba, H., Imamura, T., Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin. Cancer Res. 19 (2013), 2004–2013.
88. Nunez-Cruz, S., Gimotty, P.A., Guerra, M.W., Connolly, D.C., Wu, Y.Q., DeAngelis, R.A., Lambris, J.D., Coukos, G., Scholler, N., Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 14 (2012), 994–1004.
89. Odening, K.E., Li, W., Rutz, R., Laufs, S., Fruehauf, S., Fishelson, Z., Kirschfink, M., Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells. Clin. Exp. Immunol. 155 (2009), 239–248.
90. Okroj, M., Hsu, Y.F., Ajona, D., Pio, R., Blom, A.M., Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol. Immunol. 45 (2008), 169–179.
91. Okroj, M., Corrales, L., Stokowska, A., Pio, R., Blom, A.M., Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack. Cancer Immunol. Immunother. 58 (2009), 1771–1780.
92. Okroj, M., Holmquist, E., Nilsson, E., Anagnostaki, L., Jirstrom, K., Blom, A.M., Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence. Cancer Immunol. Immunother. 64 (2015), 467–478.
93. Park, J.W., Benz, C.C., Martin, F.J., Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin. Oncol. 31 (2004), 196–205.
94. Pawluczkowycz, A.W., Beurskens, F.J., Beum, P.V., Lindorfer, M.A., van de Winkel, J.G., Parren, P.W., Taylor, R.P., Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 183 (2009), 749–758.
95. Piao, C., Cai, L., Qiu, S., Jia, L., Song, W., Du, J., Complement 5a enhances hepatic metastases of colon cancer via monocyte chemoattractant protein-1-mediated inflammatory cell infiltration. J. Biol. Chem. 290 (2015), 10667–10676.
96. Pilzer, D., Fishelson, Z., Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis. Int. Immunol. 17 (2005), 1239–1248.
97. Pilzer, D., Saar, M., Koya, K., Fishelson, Z., Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity. Int. J. Cancer 126 (2010), 1428–1435.
98. Pohlmann, P.R., Mayer, I.A., Mernaugh, R., Resistance to trastuzumab in breast cancer. Clin. Cancer Res. 15 (2009), 7479–7491.
99. Ricklin, D., Hajishengallis, G., Yang, K., Lambris, J.D., Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11 (2010), 785–797.
100. Riihila, P., Nissinen, L., Farshchian, M., Kivisaari, A., Ala-aho, R., Kallajoki, M., Grenman, R., Meri, S., Peltonen, S., Peltonen, J., Kahari, V.M., Complement factor I promotes progression of cutaneous squamous cell carcinoma. J. Investig. Dermatol. 135 (2015), 579–588.
101. Rosner, T., Derer, S., Kellner, C., Dechant, M., Lohse, S., Vidarsson, G., Peipp, M., Valerius, T., An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels. Br. J. Haematol. 161 (2013), 282–286.
102. Rosner, T., Lohse, S., Peipp, M., Valerius, T., Derer, S., Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumour cells through the alternative pathway amplification loop. J. Immunol. 193 (2014), 1485–1495.
103. Rutkowski, M.J., Sughrue, M.E., Kane, A.J., Mills, S.A., Parsa, A.T., Cancer and the complement cascade. Mol. Cancer Res. 8 (2010), 1453–1465.
104. Santel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V., Durieux, B., Loffler, K., Fechtner, M., Rohl, T., Fisch, G., Dames, S., Arnold, W., Giese, K., Klippel, A., Kaufmann, J., RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther. 13 (2006), 1360–1370.
105. Santel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V., Fisch, G., Dames, S., Loffler, K., Fechtner, M., Arnold, W., Giese, K., Klippel, A., Kaufmann, J., A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 13 (2006), 1222–1234.
106. Schlesinger, M., Broman, I., Lugassy, G., The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia 10 (1996), 1509–1513.
107. Schmitt, C.A., Schwaeble, W., Wittig, B.M., Meyer zum Buschenfelde, K.H., Dippold, W.G., Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours. Eur. J. Cancer 35 (1999), 117–124.
108. Sier, C.F., Gelderman, K.A., Prins, F.A., Gorter, A., Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation. Int. J. Cancer 109 (2004), 900–908.
109. Sliwkowski, M.X., Mellman, I., Antibody therapeutics in cancer. Science 341 (2013), 1192–1198.
110. Sokoloff, M.H., Nardin, A., Solga, M.D., Lindorfer, M.A., Sutherland, W.M., Bankovich, A.J., Zhau, H.E., Chung, L.W., Taylor, R.P., Targeting of cancer cells with monoclonal antibodies specific for C3b(i). Cancer Immunol. Immunother. 49 (2000), 551–562.
111. Sorensen, R., Thiel, S., Jensenius, J.C., Mannan-binding-lectin-associated serine proteases, characteristics and disease associations. Springer Semin. Immunopathol. 27 (2005), 299–319.
112. Spiller, O.B., Criado-Garcia, O., Rodriguez De Cordoba, S., Morgan, B.P., Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin. Exp. Immunol. 121 (2000), 234–241.
113. Spitzer, D., Mitchell, L.M., Atkinson, J.P., Hourcade, D.E., Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J. Immunol. 179 (2007), 2600–2608.
114. Stapleton, N.M., Andersen, J.T., Stemerding, A.M., Bjarnarson, S.P., Verheul, R.C., Gerritsen, J., Zhao, Y., Kleijer, M., Sandlie, I., de Haas, M., Jonsdottir, I., van der Schoot, C.E., Vidarsson, G., Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat. Commun., 2, 2011, 599.
115. Strainic, M.G., Liu, J., Huang, D., An, F., Lalli, P.N., Muqim, N., Shapiro, V.S., Dubyak, G.R., Heeger, P.S., Medof, M.E., Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to navie CD4+ T cells. Immunity 28 (2008), 425–435.
116. Surace, L., Lysenko, V., Fontana, A.O., Cecconi, V., Janssen, H., Bicvic, A., Okoniewski, M., Pruschy, M., Dummer, R., Neefjes, J., Knuth, A., Gupta, A., van den Broek, M., Complement is a central mediator of radiotherapy-induced tumour-specific immunity and clinical response. Immunity 42 (2015), 767–777.
117. Takei, K., Yamazaki, T., Sawada, U., Ishizuka, H., Aizawa, S., Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk. Res. 30 (2006), 625–631.
118. Taylor, R.P., Lindorfer, M.A., The role of complement in mAb-based therapies of cancer. Methods 65 (2014), 18–27.
119. Thomas, A., Gasque, P., Vaudry, D., Gonzalez, B., Fontaine, M., Expression of a complete and functional complement system by human neuronal cells in vitro. Int. Immunol. 12 (2000), 1015–1023.
120. Timar, K.K., Pasch, M.C., van den Bosch, N.H., Jarva, H., Junnikkala, S., Meri, S., Bos, J.D., Asghar, S.S., Human keratinocytes produce the complement inhibitor factor H: synthesis is regulated by interferon-gamma. Mol. Immunol. 43 (2006), 317–325.
121. Tolentino, M.J., Brucker, A.J., Fosnot, J., Ying, G.S., Wu, I.H., Malik, G., Wan, S., Reich, S.J., Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 24 (2004), 132–138.
122. Tu, Z., Bu, H., Dennis, J.E., Lin, F., Efficient osteoclast differentiation requires local complement activation. Blood 116 (2010), 4456–4463.
123. Vadrevu, S.K., Chintala, N.K., Sharma, S.K., Sharma, P., Cleveland, C., Riediger, L., Manne, S., Fairlie, D.P., Gorczyca, W., Almanza, O., Karbowniczek, M., Markiewski, M.M., Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res. 74 (2014), 3454–3465.
124. Varela, J.C., Atkinson, C., Woolson, R., Keane, T.E., Tomlinson, S., Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. Int. J. Cancer 123 (2008), 1357–1363.
125. Varga, L., Czink, E., Miszlai, Z., Paloczi, K., Banyai, A., Szegedi, G., Fust, G., Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia. Clin. Exp. Immunol. 99 (1995), 112–116.
126. Walport, M.J., Complement. First of two parts. N. Engl. J. Med. 344 (2001), 1058–1066.
127. Walport, M.J., Complement. Second of two parts. N. Engl. J. Med. 344 (2001), 1140–1144.
128. Watson, N.F., Durrant, L.G., Madjd, Z., Ellis, I.O., Scholefield, J.H., Spendlove, I., Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol. Immunother. 55 (2006), 973–980.
129. Weiner, L.M., Bispecific antibodies in cancer therapy. Cancer J. 6:Suppl. 3 (2000), S265–S271.
130. Weiner, L.M., Surana, R., Wang, S., Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10 (2010), 317–327.
131. Wilczek, E., Rzepko, R., Nowis, D., Legat, M., Golab, J., Glab, M., Gorlewicz, A., Konopacki, F., Mazurkiewicz, M., Sladowski, D., Gornicka, B., Wasiutynski, A., Wilczynski, G.M., The possible role of factor H in colon cancer resistance to complement attack. Int. J. Cancer 122 (2008), 2030–2037.
132. Xu, Y., Narayana, S.V., Volanakis, J.E., Structural biology of the alternative pathway convertase. Immunol. Rev. 180 (2001), 123–135.
133. Xu, C., Jung, M., Burkhardt, M., Stephan, C., Schnorr, D., Loening, S., Jung, K., Dietel, M., Kristiansen, G., Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate 62 (2005), 224–232.
134. Zell, S., Geis, N., Rutz, R., Schultz, S., Giese, T., Kirschfink, M., Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin. Exp. Immunol. 150 (2007), 576–584.
135. Zhong, R.K., Kozii, R., Ball, E.D., Homologous restriction of complement-mediated cell lysis can be markedly enhanced by blocking decay-accelerating factor. Br. J. Haematol. 91 (1995), 269–274.
136. Zhou, W., The new face of anaphylatoxins in immune regulation. Immunobiology 217 (2012), 225–234.
137. Ziller, F., Macor, P., Bulla, R., Sblattero, D., Marzari, R., Tedesco, F., Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur. J. Immunol. 35 (2005), 2175–2183.
138. Zipfel, P.F., Heinen, S., Jozsi, M., Skerka, C., Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol. Immunol. 43 (2006), 97–106.